Expertise in
15
conditions

Dr. Destin R. Black

Oncology
Gynecologic Oncology Associates - South
2508 Bert Kouns Industrial Loop Ste 300, 
Shreveport, LA 
Accepting New Patients
Expertise in
15
conditions
Gynecologic Oncology Associates - South
2508 Bert Kouns Industrial Loop Ste 300, 
Shreveport, LA 

Overview

Destin Black is an Oncologist practicing medicine in Shreveport, Louisiana.

Dr. Black is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, and Splenectomy.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 6 clinical trials. Dr. Black is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in LA

Hospital Affiliations

Willis Knighton Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Gynecologic Oncology Associates - South
2508 Bert Kouns Industrial Loop Ste 300, Shreveport, LA 71118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Drug
Study Drugs: Bevacizumab, Cisplatin, Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

20 Total Publications

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Journal: Gynecologic oncology
Published: March 24, 2026
Similar Doctors
Expertise in
119
conditions
Dr. Anil Veluvolu
Hematology | Oncology
Expertise in
119
conditions
Dr. Anil Veluvolu
Hematology | Oncology
Referral may be required

Willis Knighton Hematology/Oncology North

2600 Kings Hwy Ste 300, 
Shreveport, LA 
 (7.0 miles away)
318-333-6270
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anil Veluvolu is a Hematologist and an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Veluvolu is highly rated in 119 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Colorectal Cancer, Lynch Syndrome, and Liver Embolization. Dr. Veluvolu is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Lsuhsc Shreveport

1501 Kings Hwy, 
Shreveport, LA 
 (6.5 miles away)
318-813-1431
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Burton is an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Burton is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Burton is currently accepting new patients.

Expertise in
51
conditions
Dr. Sakeer Hussain
Hematology | Oncology
Expertise in
51
conditions
Dr. Sakeer Hussain
Hematology | Oncology
Referral may be required

Lsuhsc Shreveport

1501 Kings Hwy, 
Shreveport, LA 
 (6.5 miles away)
318-813-1057
Languages Spoken:
English, Burmese, Hindi, Malay, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Sakeer Hussain is a Hematologist and an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Hussain is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Chronic Familial Neutropenia, Paget Disease of the Breast, Colorectal Cancer, and Lynch Syndrome. Dr. Hussain is currently accepting new patients.

Frequently Asked Questions about Dr. Destin R. Black

How do I make an appointment with Dr. Destin R. Black?

You can book an appointment with Dr. Destin R. Black by calling their office at 318-545-4565. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Destin R. Black a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Destin R. Black is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Destin R. Black specialize in?

While Dr. Destin R. Black is a Oncology, they have specific expertise in Endometrial Cancer, Vulvar Cancer, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Destin R. Black participate in research or clinical trials?

Yes. Dr. Destin R. Black has published 20 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Destin R. Black's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Destin R. Black accept my insurance?

Dr. Destin R. Black accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 318-545-4565 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Black's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile